HPVE6/E7mRNA联合P16Ki-67预测低级别宫颈鳞状上皮的临床价值评估  

Evaluation of Clinical Value of HPVE6/E7mRNA Combined with P16Ki-67 in Predicting Low Grade Cervical Squamous Epithelium

作　　者：江强[1] JIANG Qiang(Tai’an Cancer Prevention and Treatment Hospital,Tai’an 271000,China)

机构地区：[1]山东省泰安市肿瘤防治院,山东泰安271000

出　　处：《中国医学创新》2020年第22期63-67,共5页Medical Innovation of China

摘　　要：目的:探讨HPVE6/E7mRNA联合P16Ki-67预测低级别宫颈鳞状上皮的临床价值。方法:选取2017年1月-2019年4月在本院进行妇科检查的低级别宫颈鳞状上皮病变患者220例,以宫颈病理学为标准,对患者进行HPVE6/E7mRNA检测、P16Ki-67双染色及联合检测,比较P16Ki-67与HPVE6/E7mRNA的阳性检测率以及单一检测与联合检测对高级别宫颈鳞状上皮病变及以上患者的诊断效能。结果:HPVE6/E7mRNA宫颈炎、LSIL检测阳性率分别为13.64%、22.34%,P16Ki-67宫颈炎、LSIL检测阳性率分别为4.55%、10.64%,两组比较差异均有统计学意义(P<0.05)。HPVE6/E7mRNA HSIL、宫颈癌检测阳性率分别为80.00%、100%,P16Ki-67 HSIL、宫颈癌检测阳性率分别为77.14%、100%,两组比较差异无统计学意义(P>0.05)。联合检测灵敏度明显高于单一检测,比较差异有统计学意义(P<0.05),且联合检测约登指数较高,且特异性较高,其综合性最强。结论:HPVE6/E7mRNA联合P16Ki-67能够更好预测低级别宫颈鳞状上皮病变的进展,且针对高级别宫颈病变具有更强的敏感性,减少阴道镜转诊率,有效避免了因短暂性HPV感染的过度治疗,从而降低了监测以及治疗成本。Objective:To investigate the clinical value of HPVE6/E7mRNA combined with P16Ki-67 in the prediction of low grade cervical squamous epithelium.Method:From January 2017 to April 2019 in our hospital of department of gynaecology the less of cervical squamous epithelial lesions of 220 cases were selected.On the basis of cervical pathology,they were given HPVE6/E7mRNA test,P16Ki-67 double staining and joint detection.P16Ki-67 with HPVE6/E7mRNA positive detection rate,and a single detection with joint detection in patients with high level cervical squamous epithelial lesions and above diagnostic efficiency of patients were compared.Result:The positive rates of HPVE6/E7mRNA cervicitis and LSIL were 13.64%and 22.34%,respectively,the positive rates of P16Ki-67 cervicitis and LSIL were 4.55%and 10.64%,respectively,with significant differences between the two groups(P>0.05).The positive rates of HPVE6/E7mRNA HSIL and cervical cancer detection were 80.00%and 100%,respectively,the positive rates of P16Ki-67 HSIL and cervical cancer detection were 77.14%and 100%,respectively,with no statistical difference between the two groups(P>0.05).The sensitivity of the combined test was significantly higher than that of the single test,with a significant difference(P<0.05).Moreover,the combined test had a higher Yoden index,higher specificity,and the most comprehensive.Conclusion:HPVE6/E7mRNA combined with P16Ki-67 can better predict the progress of low grade cervical squamous lesions,and has a stronger sensitivity for high grade cervical lesions,reduce the colgoscopy referral rate,effectively avoid over treatment due to transient HPV infection,thereby reducing the monitoring and treatment costs.

关 键 词：HPVE6/E7mRNA 检测 P16Ki-67 检测 低级别宫颈鳞状上皮病变 

分 类 号：R737.33[医药卫生—肿瘤]